Cargando…

Role of P-glycoprotein on CD69(+)CD4(+) cells in the pathogenesis of proliferative lupus nephritis and non-responsiveness to immunosuppressive therapy

INTRODUCTION: P-glycoprotein (P-gp) expression on activated lymphocytes in systemic lupus erythematosus (SLE) plays a role in active efflux of intracellular drugs, resulting in drug resistance. The role of P-gp-expressing lymphocytes in the pathogenesis of SLE remains unclear. The aim of this study...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tsujimura, Shizuyo, Adachi, Tomoko, Saito, Kazuyoshi, Tanaka, Yoshiya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	RMD Open 2017
Materias:	Lupus
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5708311/ https://www.ncbi.nlm.nih.gov/pubmed/29225917 http://dx.doi.org/10.1136/rmdopen-2016-000423

Ejemplares similares

Treatment with Methotrexate and Intravenous Cyclophosphamide Pulse Therapy Regulates the P-gp(+)CD4(+) Cell-related Pathogenesis in a Representative Patient with Refractory Proliferative Lupus Nephritis
por: Tsujimura, Shizuyo, et al.
Publicado: (2019)

Efficacy of Intravenous Cyclophosphamide Pulse Therapy for P-Glycoprotein-expressing B Cell-associated Active True Renal Lupus Vasculitis in Lupus Nephritis
por: Kawabe, Akio, et al.
Publicado: (2017)

Interleukin (IL) 16: a candidate urinary biomarker for proliferative lupus nephritis
por: Häyry, Aliisa, et al.
Publicado: (2022)

Differential expression of IFN-α, IL-12 and BAFF on renal immune cells and its relevance to disease activity and treatment responsiveness in patients with proliferative lupus nephritis
por: Nawata, Aya, et al.
Publicado: (2023)

Discovery of NEU1 as a candidate renal biomarker for proliferative lupus nephritis chronicity
por: Mao, Zhaomin, et al.
Publicado: (2021)

Viewpoint on anifrolumab in patients with systemic lupus erythematosus and a high unmet need in clinical practice
por: Tanaka, Yoshiya
Publicado: (2023)

Dissecting signalling pathways associated with intrarenal synthesis of complement components in lupus nephritis
por: Tampe, Desiree, et al.
Publicado: (2022)

Worse long-term renal outcome of lupus nephritis patients of African descent living in Europe
por: Enfrein, Antoine, et al.
Publicado: (2022)

Four trajectories of 24-hour urine protein levels in real-world lupus nephritis cohorts
por: Zhang, Danting, et al.
Publicado: (2023)

Differences and similarities of proliferative and non-proliferative forms of biopsy-proven lupus nephritis: Single centre, cross-disciplinary experience
por: Duran, Emine, et al.
Publicado: (2022)

A multicentre, randomised controlled study of enteric-coated mycophenolate sodium for the treatment of relapsed or resistant proliferative lupus nephritis: an Asian experience
por: Anutrakulchai, Sirirat, et al.
Publicado: (2016)

High p16(INK4a), a marker of cellular senescence, is associated with renal injury, impairment and outcome in lupus nephritis
por: Tilman, Gaëlle, et al.
Publicado: (2021)

Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): results of a multicentre randomised controlled trial
por: Jourde-Chiche, Noemie, et al.
Publicado: (2022)

Value of repeat biopsy in lupus nephritis flares
por: Greloni, G, et al.
Publicado: (2014)

Safety profile of baricitinib in patients with systemic lupus erythematosus: an integrated analysis
por: Morand, Eric, et al.
Publicado: (2023)

Clinical measurement of lupus nephritis activity is inferior to biomarker-based activity assessment using the renal activity index for lupus nephritis in childhood-onset systemic lupus erythematosus
por: Aljaberi, Najla, et al.
Publicado: (2022)

Urine and serum S100A8/A9 and S100A12 associate with active lupus nephritis and may predict response to rituximab treatment
por: Davies, Jennifer C, et al.
Publicado: (2020)

Role of early repeated renal biopsies in lupus nephritis
por: Zickert, A, et al.
Publicado: (2014)

Interferon (IFN)-λ is a potential mediator in lupus nephritis
por: Zickert, Agneta, et al.
Publicado: (2016)

Management of lupus nephritis: a systematic literature review informing the 2019 update of the joint EULAR and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations
por: Kostopoulou, Myrto, et al.
Publicado: (2020)

B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial
por: Furie, Richard A, et al.
Publicado: (2022)

Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea
por: Tanaka, Yoshiya, et al.
Publicado: (2021)

Causes and predictors of mortality in biopsy-proven lupus nephritis: the Sarawak experience
por: Teh, Cheng Lay, et al.
Publicado: (2018)

Outcome of participants with nephrotic syndrome in combined clinical trials of lupus nephritis
por: Gomez Mendez, Liliana Michelle, et al.
Publicado: (2019)

Immune gene expression and functional networks in distinct lupus nephritis classes
por: Gilmore, Alyssa C, et al.
Publicado: (2022)

Remission of lupus nephritis: the trajectory of histological response in successfully treated patients
por: Malvar, Ana, et al.
Publicado: (2023)

Serum albumin at 1 year predicts long-term renal outcome in lupus nephritis
por: Domingues, Vinicius, et al.
Publicado: (2018)

Predictors of increase in chronicity index and of kidney function impairment at repeat biopsy in lupus nephritis
por: Moroni, Gabriella, et al.
Publicado: (2022)

Performance of the 2019 EULAR/ACR systemic lupus erythematosus classification criteria in a cohort of patients with biopsy-confirmed lupus nephritis
por: Wang, Huijing, et al.
Publicado: (2021)

Multicentre retrospective cohort study assessing the incidence of serious infections in patients with lupus nephritis, compared with non-renal systemic lupus erythematosus
por: Yates, Drew Joseph, et al.
Publicado: (2020)

Identification of clinical and serological factors during induction treatment of lupus nephritis that are associated with renal outcome
por: Dall'Era, Maria, et al.
Publicado: (2015)

Urinary markers differentially associate with kidney inflammatory activity and chronicity measures in patients with lupus nephritis
por: Akhgar, Ahmad, et al.
Publicado: (2023)

Glomerular mTORC1 activation was associated with podocytes to endothelial cells communication in lupus nephritis
por: Liu, Xiaotian, et al.
Publicado: (2023)

Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial
por: Jayne, David, et al.
Publicado: (2023)

Renal response at 2 years post biopsy to predict long-term renal survival in lupus nephritis: a retrospective analysis of the Hopkins Lupus Cohort
por: Cooper Blenkinsopp, Selin, et al.
Publicado: (2022)

Escaping the catch 22 of lupus anticoagulant testing
por: Vinholt, Pernille Just, et al.
Publicado: (2020)

Pathogenic autoantibodies from patients with lupus nephritis cause reduced tyrosine phosphorylation of podocyte proteins, including tubulin
por: Manson, Jessica J, et al.
Publicado: (2014)

Urinary HER2, TWEAK and VCAM-1 levels are associated with new-onset proteinuria in paediatric lupus nephritis
por: Costa-Reis, Patricia, et al.
Publicado: (2022)

Response to therapy at 6 months predicts long-term renal outcome in lupus nephritis with poor kidney function
por: Luo, Huiting, et al.
Publicado: (2022)

Predictors of renal damage in systemic lupus erythematous patients: data from a multiethnic, multinational Latin American lupus cohort (GLADEL)
por: Reátegui-Sokolova, Cristina, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6npo1goocl403jbp65dar6qspl